ARCH Venture Fund XII, L.P. → Prime Medicine, Inc. PRME

Stake: 10.40% Shares: 18,587,036 CUSIP: 74168J101 Class: Common Stock, $0.00001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-03-31

DTC 11.27

29,959,086 shares short · +11.8% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $1.91M

Point72 Asset Mgmt

Other Filings by ARCH Venture Fund XII, L.P.

Filed	Form	Issuer	Stake	Shares
2026-04-01	SCHEDULE 13D/A	Neumora Therapeutics, Inc. NMRA	18.70%	33,847,838	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →